Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives
This study is ongoing, but not recruiting participants.
First Posted: June 10, 2010
Last Update Posted: April 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by (Responsible Party):
Siew Chien NG, Chinese University of Hong Kong
The aim of this study is to compare the gut microbiota in Chinese patients with Inflammatory Bowel Disease (IBD) in Hong Kong with that of healthy controls, compare the gut microbiota in IBD patients in a developing country (low but increasing IBD incidence, Hong Kong) with those in a developed country (high incidence, Australia), compare the gut microbiota in Chinese patients with IBD in Hong Kong with the microbiota of their non-IBD affected parents and siblings.
Inflammatory Bowel Disease
||Observational Model: Case-Control
Time Perspective: Prospective
||A Study of the Gut Microbiota in the Healthy Population, Patients With Inflammatory Bowel Disease and Their Relatives (IBD Microbe Study
Primary Outcome Measures:
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
- To identify environmental risk factors [ Time Frame: 2 years ]
A validated Enviromental risk factor questionnaire by International Organisation of Inflammatory Bowel Disease
- To identify genetic differences among IBD patients, their relatives and the control subjects [ Time Frame: 2 years ]
To measure common known genetic variants including NOD2 mutation, IL23R, TNFSF15, etc from blood samples
- To identify disease characteristics among IBD patients [ Time Frame: 2 years ]
Disease characteristics including disease behavior, disease location and progression according to Montreal Classification.
Serum DNA will be collected and stored only if patients have provided consent separately. All serum DNA blood samples will be anonymised. Genetic results will not be made available to individual patients in a future date as there is no evidence to support genetic testing for risk prediction in routine practice, but these large scale genetic results will be useful to identify relevant future therapeutic targets for treatment of IBD. 10 ml of blood will be collected in EDTA tubes and stored at minus 80 degrees C, These samples will be transported to China for analysis at a later date.
| Estimated Enrollment:
| Actual Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||May 2017 (Final data collection date for primary outcome measure)
Crohn's disease or ulcerative colitis patients
Healthy controls (non-IBD)
Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
Relatives of IBD patients
They will be a first degree relative of a IBD patient.
Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gut that cause major life-long disability. Afflicting mostly young people at an age when they are most active both in their private and professional life, inflammatory bowel disease (IBD) represents an important public health problem affecting both the patients education, working abilities, social life and quality of life. Previously a disease predominantly of the West, there is now a marked increase in the incidence of IBD in Hong Kong. The cause of this dramatic increase over the last decade is unknown. Genetic factors, environmental factors and the gut bacteria may play a role in disease development. This study aims to explore the factors that may be contributing to, or causing, the rise of IBD in Hong Kong. The investigators propose to study the gut bacteria in Chinese patients with IBD compared with non-IBD patients, and healthy relatives of IBD patients. IBD patients will be prospectively recruited, blood samples will be obtained for serology and genotyping, stool samples and biopsies will be collected during routine colonoscopy for microbiota analysis. Bloods, stool and tissue gut microbiota from non-IBD patients will be collected for comparison. Studying gut microbiota, genetics and environmental factors in populations with changing incidence of IBD offers the greatest hope of identifying potentially important causative factors for disease.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Crohn's disease or ulcerative colitis patients as the case groups, Patients attend clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy as the control group, and the first degree relatives of IBD patients as the relative group
- patients aged ≥18 with a diagnosis of Crohn's disease or ulcerative colitis defined by endoscopy, radiology and histology, patients on stable medication and informed consent obtained
Healthy controls (non-IBD patients) will comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding. Controls will be excluded if they have previously been diagnosed with IBD or if they have a first or second degree relative with IBD.
Relatives of patients will be aged between 16 and 35 years. They will be a first degree relative of a patient. Relatives older than 35 will not be recruited to maximise the chance of including some individuals who will develop IBD in the future. Relatives will be contacted either via the patient or directly by telephone by the investigators. They will be invited to attend for a screening meeting to assess eligibility and to receive the information sheets. They will undergo a flexible sigmoidoscopy/colonoscopy for biopsies once fully consented.
- current infection with an enteric pathogen,
- use of antibiotics within the last month,
- consumption of any probiotic or prebiotic within the last month,
- imminent need for surgery,
- requiring hospitalization,
- pregnancy or lactation,
- short bowel syndrome
- previous proctocolectomy
- significant hepatic, renal, endocrine, respiratory, neurological or cardiovascular disease as determined by the principal investigator,
- if they have a history of cancer with a disease free state of less than two years
Control and Relative group:
- previously been diagnosed with IBD
- they have a first or second degree relative with IBD
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01140802
|Prince of Wales Hospital
|Hong Kong, Hong Kong |
Chinese University of Hong Kong
||Siew C NG, PhD
||Chinese University of Hong Kong
||Siew Chien NG, Professor, Chinese University of Hong Kong
History of Changes
|Other Study ID Numbers:
||June 8, 2010
||June 10, 2010
|Last Update Posted:
||April 25, 2017
|Individual Participant Data (IPD) Sharing Statement:
|Plan to Share IPD:
Keywords provided by Siew Chien NG, Chinese University of Hong Kong:
First degree relatives
Additional relevant MeSH terms:
Inflammatory Bowel Diseases
Digestive System Diseases